By making intelligent connections, we bring innovation to the needs of today’s oncology development to help you focus on the patient, manage trial complexity, and increase predictability and speed. IQVIA helps you
Oncology drug development is shifting from a drug-centered approach to a patient-centered one. From dose escalation through dose optimization, IQVIA's expertise helps you navigate the evolving oncology landscape and make informed decisions quickly.
Regulatory approvals (FDA, PMDA, MHRA, EC) across 14 indications in oncology from 2020-2023
Of FDA-approved oncology drugs between 2016 and 2024 involved IQVIA
Of FDA-approved hematology drugs between 2016 and 2024 involved IQVIA
Therapeutically aligned solutions to advance your clinical program to the next milestone.
Access new resources for advanced therapy development, from candidate identification through market authorization.
Predict enrollment more accurately and increase the number of patients per site using data-driven patient recruitment solutions.
Access central labs around the globe through IQVIA Laboratories Solutions, a wholly owned subsidiary of IQVIA.
Unravel the complexities of cancer treatment with patient-level data-driven solutions.
Access a dedicated network of European cancer hospitals to capture real world data that reflects the latest clinical practice and perform oncology studies faster.
Oncology and hematology programs demand specialized expertise and coordinated support across every stage of development, from early phase studies through regulatory approval. IQVIA combines biomarker strategy, adaptive trial design, patient-centered recruitment, real-world evidence, and advanced analytics to help sponsors address these challenges.
IQVIA has supported programs of varying sizes and complexities, with involvement in 84% of FDA-approved oncology drugs and 95% of FDA-approved hematology drugs since 2016. Explore more oncology insights from our team of experience subject matter experts.
Developing hematology therapies often requires specialized expertise, global coordination, and the ability to address the unique challenges of both blood cancers and non-malignant blood disorders. IQVIA supports programs from first-in-human studies through global registration, with specialists spanning the full spectrum of hematologic diseases.
Support includes advanced lab and biomarker services, global site networks, adaptive trial designs, and specialized technologies to help sponsors navigate the complexities of hematology development and work toward improved patient outcomes.
Oncology programs vary widely in complexity, modality, and stage of development. IQVIA supports clinical trials across all phases, from Phase I through Phase III/IV, including both treatment and prevention studies.
Experience spans immuno-oncology, targeted therapies, cell and gene therapies, pediatric oncology, and rare cancers, helping sponsors address diverse development challenges.
Bringing oncology therapies from concept to commercialization requires coordination across multiple stages of development. IQVIA supports programs end to end, beginning with trial planning and design, including protocol development and IND/CTA filings, and extending through site selection, patient recruitment, and trial execution.
Additional support includes specialty lab and biomarker services, regulatory oversight, and post-trial activities such as real-world evidence generation and commercialization insights. IQVIA’s scale of expertise and technology, can help you bring treatments to those in need, faster.
Modern oncology development requires integrating scientific, operational, and patient-focused strategies throughout the trial lifecycle. IQVIA can help you incorporate biomarker strategies, apply patient insights, execute adaptive trial designs, and deliver cell and gene therapy programs.
Development plans can also be informed by real-world and commercial insights, with AI and machine learning capabilities helping improve trial efficiency and support patient safety.
.svg){kind=icon}
